CompletedPhase 4

Sugammadex ED90 Dose in the Obese Patients

31 participantsStarted 2013-01

Plain-language summary

The purpose of this study is to determine the minimum effective dose of sugammadex, an antagonist of neuromuscular blockade used during anesthesia practice, in obese patients, considering that sugammadex is indicated in adults with normal weight at a dose of 2 mg/kg but no studies were found with obese patients.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * a body mass index ≥ 40 kg/m2 * bariatric surgery * informed consent signed Exclusion Criteria: * history of neuromuscular diseases, * use of drugs that could interfere with neuromuscular transmission, * allergy to neuromuscular agents of the aminosteroids class, * anticipated difficulty in airway management, * renal failure

What they're measuring

Sugammadex ED90

Timeframe: 8 minutes

Trial details

NCT IDNCT02568345

SponsorFaculdade de Ciências Médicas da Santa Casa de São Paulo

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-10

Results submitted2015-10-06

View on ClinicalTrials.gov More Incomplete Reversal of Neuromuscular Block trials